CollPlant Biotechnologies (CLGN) Equity Ratio (2018 - 2025)

CollPlant Biotechnologies' Equity Ratio history spans 8 years, with the latest figure at 0.56 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 21.65% year-over-year to 0.56; the TTM value through Dec 2025 reached 0.56, down 21.65%, while the annual FY2025 figure was 0.56, 21.65% down from the prior year.
  • Equity Ratio reached 0.56 in Q4 2025 per CLGN's latest filing, down from 0.72 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.88 in Q4 2021 to a low of 0.56 in Q4 2025.
  • Average Equity Ratio over 5 years is 0.77, with a median of 0.83 recorded in 2023.
  • Peak YoY movement for Equity Ratio: soared 113.3% in 2021, then fell 21.65% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.88 in 2021, then fell by 2.97% to 0.85 in 2022, then dropped by 2.84% to 0.83 in 2023, then dropped by 13.34% to 0.72 in 2024, then decreased by 21.65% to 0.56 in 2025.
  • Per Business Quant, the three most recent readings for CLGN's Equity Ratio are 0.56 (Q4 2025), 0.72 (Q4 2024), and 0.83 (Q4 2023).